Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AbbVie Expects 9% Tax Rate, Thanks To US Tax Reform Law

Executive Summary

The tax reform windfall makes an already strong fourth quarter and full year 2017 financial report more impressive for AbbVie, which reported continuing growth for Humira and Imbruvica, and a big uptick in HCV.

Advertisement

Related Content

How Is Pharma Spending Tax Savings? Not On Drug Pricing, Sen. Booker Says
Pharma Q4 Results Preview: Bristol, Allergan, Gilead, GSK, Sanofi, Teva
J&J Shows Grace Under Pressure From Biosimilars And Other Threats
A Different Approach To Corporate Venture: An Interview With AbbVie Ventures' Scott Brun
New AbbVie Guidance Sets High Bar For Post-Humira Pipeline
AbbVie's Mavyret Is First 8-Week Pan-Genotypic Combination For HCV

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC100279

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel